Shares of Juno Therapeutics Inc. (JUNO) rose over 24% in extended trading on Tuesday, following the removal of FDA clinical hold on the company's phase II clinical trial of JCAR015 in adult patients with relapsed or refractory B cell acute lymphoblastic leukemia.
from RTT - Biotech http://ift.tt/29CKsNp
via IFTTT
No comments:
Post a Comment